F. L. Meyskens

Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.

Dennis J. Ahnen, Polly Feigl, G. Quan et al. · PubMed · 1998 · 349 citations

Tumor Biology, Ki-ras Mutation, Cancer Epidemiology +15

Development of difluoromethylornithine (DFMO) as a chemoprevention agent.

F. L. Meyskens, Eugene W. Gerner · PubMed · 1999 · 339 citations

Medicinal Chemistry, Chemoprevention Strategy, Biochemistry +15

Enhancement of Regression of Cervical Intraepithelial Neoplasia II (Moderate Dysplasia) With Topically Applied All- trans -Retinoic Acid: a Randomized Trial

F. L. Meyskens, Earl A. Surwit, Thomas E. Moon et al. · JNCI Journal of the National Cancer Institute · 1994 · 268 citations

Phase I-II study of 13-cis-retinoic acid in myelodysplastic syndrome.

Bernard R. Greenberg, B G M Durie, Tammy Barnett et al. · PubMed · 1985 · 52 citations

Hematological Malignancy, Thrombosis, Medicine +14

Phase I trial of retinol in cancer patients.

Gary E. Goodman, D S Alberts, D L Earnst et al. · Journal of Clinical Oncology · 1983 · 43 citations

Chemoprevention Strategy, Cancer Management, Pharmacotherapy +16